US Pharma MarketingAlnylam rebuked by FDA over efficacy claims on Amvuttra website
The FDA has hit (PDF) Alnylam with an untitled letter over the consumer website for Amvuttra, accusing the biotech The FDA has hit Alnylam with an untitled letter over the consumer website for Amvuttra, accusing the biotech of presenting open-label data that create a misleading impression of the drug’s effects.
The FDA has hit Alnylam with an untitled letter over the consumer website for Amvuttra, accusing the biotech of presenting open-label data that create a misleading impression of the drug’s effects.
Source: FiercePharma